Ian E. Krop, MD, PhD, discusses the importance of clinical trials further exploring the role of trastuzumab deruxtecan following the FDA ’s approval of the agent as treatment of patients with HER2-positive metastatic breast cancer.
Videos
Leora Horn, MD, MSc, discusses the real-world data outcomes compared with clinical trial data of mobocertinib from a retrospective study in patients with refractory non–small cell lung cancer with EGFR exon 20 insertions.
Ainhoa Madariaga, MD, discusses the data from the phase 1/2 HYDRA-01 trial looking at hydroxychloroquine and itraconazole in patients with advanced platinum-resistant epithelial ovarian cancer.
Marcia Brose, MD, PhD, discusses the safety findings from an analysis of larotrectinib as treatment of patients with metastatic solid tumors.
A discussion on a novel therapeutic target for treatment, known as exportin 1 (XPO1), and the first selective nuclear export inhibitor to enter clinical use for patients who have developed relapse after IMiD and protease inhibitor therapies.
Jared Weiss, MD, discusses the pooled analysis of 3 phase 2 trials looking at trilaciclib in patients with extensive-stage small cell lung cancer.
An expert oncologist presents the case of a 69-year-old woman with advanced renal cell carcinoma, and considers available treatment options for patients with a similar disease setting.
Irene Ghobrial, MD, discusses the importance of the data made available through the Multiple Myeloma Research Foundation’s CureCloud research study.
David Reardon, MD, discusses the interim results and toxicity with INO-5401 and INO-9012 delivered intramuscularly with electroporation in combination with cemiplimab in patients with newly diagnosed glioblastoma.
Lori A. Leslie, MD, discusses options for patients with relapsed/refractory mantle cell lymphoma.
Terry P. Mamounas, MD, MPH, discusses the use of extended adjuvant therapy for patients with breast cancer and how the landscape is evolving.
Christian U. Blank, MD, PhD, discusses the most recent data from the phase 1b OpACIN trial of ipilimumab and nivolumab in patients with macroscopic stage III melanoma.
Heinz-Josef Lenz, MD, discusses the significance of conducting biomarker testing in patients with metastatic colorectal cancer in accordance with the results of the phase 2 CheckMate-142 trial.
Richard R. Furman, MD, discusses the distinguishing features between the 3 different Bruton’s tyrosine kinase inhibitors as treatment of patients with B-cell malignancies.
